Cullinan Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Michaelson Jennifer unloaded Company’s shares for reported $49200.0 on Jan 22 ’26. In the deal valued at $12.30 per share,4,000 shares were sold. As a result of this transaction, Michaelson Jennifer now holds 128,635 shares worth roughly $1.61 million.
Then, JENNIFER MICHAELSON bought 4,000 shares, generating $46,400 in total proceeds.
Before that, AHMED NADIM sold 9,922 shares. Cullinan Therapeutics Inc shares valued at $99,319 were divested by the President and CEO at a price of $10.01 per share. As a result of the transaction, AHMED NADIM now holds 420,699 shares, worth roughly $5.26 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Friday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -0.56% to $12.5. Over the last five days, the stock has gained 17.26%. Cullinan Therapeutics Inc shares have risen nearly 18.93% since the year began. Nevertheless, the stocks have risen 20.77% over the past one year.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-12-31, growing by 1.26 million shares to a total of 8.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 6.88 million shares. There was a rise of 15.48%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
